[Click eStock] "LegoChem Bio, Continuous Pipeline Research Achievements"

[Asia Economy Reporter Hwang Yoon-joo] Shinhan Financial Investment maintained a 'Buy' rating and a target price of 82,000 KRW for LegoChem Biosciences on the 17th, stating that the pipeline performance will continue this year.

Researcher Lee Dong-geon of Shinhan Financial Investment stated, "At the American Association for Cancer Research (AACR), superior anticancer effects were confirmed in the research results of four pipelines applying LegoChem Biosciences' antibody-drug conjugate (ADC) platform."

Researcher Lee explained that for 'IKS014', a 'HER2' breast cancer treatment, "Our partner, UK-based Exscientia, secured superiority over the competing pipeline Enhertu in in-vivo and in-vitro animal experiments, as well as the stability of LegoChem Biosciences' linker technology and a stable PK and tolerability profile."

He also stated, "Excellent tumor suppression effects and tolerability were demonstrated in preclinical studies targeting diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) models for 'IKS03'." 'IKS03' was licensed to UK-based Exscientia and targets CD19, with B-cell lymphoma as its indication.

He evaluated, "Tolerability was confirmed in colon, stomach, and pancreatic cancer models for the candidate 'CanAg ADC', which was the first to be derived after the ADC platform technology transfer with Exscientia."

Researcher Lee added, "Starting with AACR, pipeline performance is expected to continue with the announcement of HER2 ADC China Phase 1a results within the year and successive global clinical trial initiations by partners."